Login / Signup

GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.

Frederick M LangKevin M C LeeJohn R TeijaroBurkhard BecherJohn A Hamilton
Published in: Nature reviews. Immunology (2020)
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.
Keyphrases
  • coronavirus disease
  • growth factor
  • sars cov
  • clinical trial
  • respiratory syndrome coronavirus
  • adipose tissue
  • cerebrospinal fluid
  • randomized controlled trial
  • small molecule
  • peripheral blood
  • double blind